Necitumumab: a new option for first-line treatment of squamous cell lung cancer

Expert Opinion on Drug Metabolism & Toxicology
Elizabeth Jiménez AguilarLuis Paz-Ares Rodríguez

Abstract

First-line treatment with platinum-based chemotherapy has been the standard treatment for non-small-cell lung cancer (NSCLC) during the past decades. The development of new targeted drugs based on molecular alterations (EGFR, ALK, and ROS1) has led to important outcome benefits, but not for squamous cell carcinoma (SCC). However, the aberrant function of the EGFR pathway in SCC may be important in the development of the tumor and has been explored in preclinical and clinical studies as a potential target. Areas covered: Necitumumab is a human IgG1 anti-EGFR antibody that binds to the receptor and inhibits further pathway activation, thereby inhibiting cell differentiation, proliferation and migration. The phase III SQUIRE trial was a randomized study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone for first-line stage IV squamous NSCLC, showing a higher overall survival and better disease control with the addition of necitumumab. Despite the good results, the lack of robust predictive biomarkers makes the selection of the patients who will benefit the most complex. Expert opinion: Necitumumab plus cisplatin-gemcitabine is a first-line treatment option in SCC that improves overall survival and preser...Continue Reading

References

Mar 31, 2000·Nature Medicine·A N Houghton, D A Scheinberg
Nov 1, 2000·Cell·J Schlessinger
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Sep 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fred R HirschWilbur A Franklin
Dec 24, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David G PfisterUNKNOWN American Society of Clinical Oncology
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe GiacconeDavid H Johnson
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstDavid H Johnson
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H JohnsonFairooz Kabbinavar
Jul 14, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S Segaert, E Van Cutsem
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jul 27, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstUNKNOWN TRIBUTE Investigator Group
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jun KuraiEiji Shimizu
Dec 3, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Ana Victoria López-MalpartidaJosé García Pichel
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas J LynchDonald Woytowitz
Mar 4, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bart KuenenEmile E Voest
Nov 27, 2010·Critical Reviews in Oncology/hematology·Robert Pirker, Martin Filipits
Jun 18, 2011·Expert Opinion on Biological Therapy·Rodrigo Dienstmann, Enriqueta Felip
Sep 11, 2012·Nature·UNKNOWN Cancer Genome Atlas Research Network
Oct 12, 2012·Journal of the National Comprehensive Cancer Network : JNCCN·David S EttingerUNKNOWN NCCN (National Comprehensive Cancer Network)
May 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David R GandaraFred R Hirsch
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Aug 28, 2015·JAMA Oncology·Daniel A GoldsteinChristopher R Flowers
Sep 16, 2015·Cancers·Vishal BoolellVinod Ganju
Dec 15, 2015·Global Journal of Health Science·Roshanak VameghiHamid Alavimajd
Jan 6, 2016·Drugs·Karly P Garnock-Jones
Mar 17, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Martin ReckNick Thatcher
May 12, 2016·The New England Journal of Medicine·Charles Swanton, Ramaswamy Govindan
Jun 15, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Mark A SocinskiNick Thatcher
Oct 19, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Corey J LangerNick Thatcher
Oct 4, 2016·Clinical Pharmacokinetics·Amanda LongJohan Wallin
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators

❮ Previous
Next ❯

Citations

Dec 12, 2019·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Irena IlicMilena Ilic
Apr 10, 2021·Cell Death & Disease·Jing XuMengmeng Niu
Oct 6, 2020·The American Journal of the Medical Sciences·Tong-Jia ZhangShu-Yan Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.